Ireland's Health Service Executive (HSE) has agreed to fund the drug Skyclarys for patients suffering from Friedreich's Ataxia [1, 2].
The decision provides access to a specialized treatment for a rare genetic condition, though officials said the drug's efficacy remains limited [2, 4].
The funding approval follows a review process that began earlier this month. The HSE Drugs Group first met to discuss the medication on Aug. 11, 2026 [3]. Following that meeting, the HSE Senior Management Team finalized the decision, which was announced on Aug. 25, 2026 [1, 2].
Officials said the approval was driven by pricing negotiations with the pharmaceutical company Biogen. A spokesperson for the HSE said the decision "took account of a substantially improved financial offer made in recent days by the company Biogen" [2].
Friedreich's Ataxia is a rare disease that causes progressive damage to the nervous system. While some reports describe Skyclarys as a life-saving drug [2], the HSE maintained a more cautious stance regarding its clinical impact [2, 4]. The tension between the drug's cost and its limited efficacy had previously been a point of contention in the funding review [4].
The move comes after patient advocacy and pressure to make the treatment available within the Irish healthcare system. By securing a lower price from Biogen, the HSE was able to move forward with the funding despite the limited efficacy noted in clinical data [2, 4].
“The HSE has agreed to fund the drug Skyclarys for patients with Friedreich's Ataxia.”
This decision highlights the ongoing struggle between national health services and pharmaceutical companies over the pricing of orphan drugs. By conditioning funding on a 'substantially improved financial offer,' the HSE demonstrates a strategy of leveraging patient demand to lower the cost of treatments that have high price tags but limited proven clinical efficacy.
